- Home
- TRC vs VSTM Comparison
TRC vs VSTM Comparison
Compare TRC & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TRC | VSTM |
|---|---|---|
| Founded | 1843 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 476.6M | 470.7M |
| IPO Year | 1995 | 2011 |
Fundamental Metrics
Financial Performance| Metric | TRC | VSTM |
|---|---|---|
| Price | $18.99 | $5.54 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 98.5K | ★ 1.4M |
| Earning Date | 01-01-0001 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 17.49 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $37,830,000.00 | $30,914,000.00 |
| Revenue This Year | $2.31 | $254.18 |
| Revenue Next Year | N/A | $99.39 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 209.14 |
| 52 Week Low | $15.04 | $4.01 |
| 52 Week High | $19.53 | $11.25 |
Technical Indicators
Market Signals| Indicator | TRC | VSTM |
|---|---|---|
| Relative Strength Index (RSI) | 69.36 | 39.29 |
| Support Level | $15.56 | $5.56 |
| Resistance Level | $19.20 | $6.66 |
| Average True Range (ATR) | 0.57 | 0.34 |
| MACD | 0.10 | 0.01 |
| Stochastic Oscillator | 73.54 | 10.28 |
Price Performance
Historical ComparisonAbout TRC Tejon Ranch Co
Tejon Ranch Co is a diversified real estate development and agribusiness company committed to responsibly using its land and resources to meet the housing, employment, and lifestyle needs of Californians and create value for its shareholders. It has five segments namely Real Estate - Commercial/Industrial, Real Estate - Resort/Residential, Mineral Resources, Farming, and Ranch Operations.
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.